Cabometyx and Opdivo still superior to sunitinib in advanced renal cell carcinoma

15 February 2022

French drugmaker Ipsen (Euronext: IPN) has announced two-year follow-up results from analyses of the Phase III CheckMate -9ER trial.

The study showed sustained survival and response rate benefits, as well as health-related quality of life (HRQoL) improvements, with the combination of Ipsen’s Cabometyx (cabozantinib) and Bristol Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab) versus sunitinib in the first-line treatment of advanced renal cell carcinoma.

"There has been a dramatic evolution in the treatment landscape across lines of therapy for people living with renal cell carcinoma over recent years"As well as the sustained efficacy and tumor shrinkage benefits with Cabometyx in combination with Opdivo compared to sunitinib and the HRQoL improvements, the trial found a consistent safety profile with that previously observed for the two drugs together.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK